23 Feb uniQure
Richard Porter, Ph.D., Chief Business and Scientific Officer
April 10 | 3:45pm | Salone dei Cavalieri, Section 3&4
Amsterdam, Netherlands
(NASDAQ: QURE)
uniQure is delivering on the promise of gene therapy a single treatment with potentially curative results through an innovative adeno-associated virus (AAV)-based technology platform supported by proprietary commercial-grade manufacturing. The recent approvals of our gene therapy for hemophilia B an historic achievement based on more than a decade of research and clinical development represent a major milestone in the field of genomic medicine and usher in a new treatment approach for patients living with hemophilia. We’re now advancing a clinical program in Huntington’s disease with a growing list of early clinical and preclinical candidates.
